To discover disease-modifying therapies for Parkinson’s disease, we are understanding how dysfunction of molecular pathways cause neurodegeneration and developing novel tools and approaches for drug discovery. Our strategy is to use multiple experimental paradigms including traditional and innovative methods, as well as collaborative approaches with interdisciplinary teams. We are creating and deploying novel models of Parkinson’s disease, in combination with artificial intelligence, to define never before discovered molecular pathways that may contribute to neurodegeneration. These models allow us to test promising small molecules, as well as biological and cell therapies, to determine if they can halt the loss of dopamine neurons and be potentially translated to new therapies for Parkinson’s disease.